Payment overview · 2025
General Payments
$438.75
22 reported records · 9 companies
Healthcare provider profile · identity verified
Kiersten Page Mullis, DO
Allopathic & Osteopathic Physicians|Family Medicine · YANCEVILLE, NC · NPI 1639632391
Verified facts
What the public records show
CMS Open Payments records show Kiersten Page Mullis, DO received $438.75 in general payments during 2025 across 22 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $113.25 | 25.8% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $90.49 | 20.6% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $51.90 | 11.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.66 | 11.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.70 | 9.7% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.55 | 6.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.87 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.75 | 4.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.58 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $438.75 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $90.49 | 4 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $75.61 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 336 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 73 |
| Metformin Hcl | Metformin Hcl | 215 | 51 |
| Lisinopril | Lisinopril | 205 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 30 |
| Jardiance | Empagliflozin | 141 | 20 |
| Gabapentin | Gabapentin | 135 | 41 |
| Losartan Potassium | Losartan Potassium | 131 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 32 |
| Famotidine | Famotidine | 119 | 29 |
| Potassium Chloride | Potassium Chloride | 113 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 16 |
| Omeprazole | Omeprazole | 107 | 29 |
| Irbesartan | Irbesartan | 98 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 25 |
| Furosemide | Furosemide | 87 | 24 |
| Allopurinol | Allopurinol | 86 | 21 |
| Carvedilol | Carvedilol | 81 | 17 |
| Chlorthalidone | Chlorthalidone | 76 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 22 |
| Ozempic | Semaglutide | 70 | 17 |
| Bupropion Xl | Bupropion Hcl | 64 | 12 |
| Sertraline Hcl | Sertraline Hcl | 64 | 13 |
| Metformin Hcl Er | Metformin Hcl | 59 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 24 |
| Glipizide | Glipizide | 51 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 14 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Simvastatin | Simvastatin | 49 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 48 | 37 |
| Eliquis | Apixaban | 45 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | 11 |
| Pregabalin | Pregabalin | 42 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 16 |
| Prednisone | Prednisone | 39 | 29 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 37 | 37 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 13 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | 13 |
| Tramadol Hcl | Tramadol Hcl | 26 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $438.75 · 22 records | Teva Pharmaceuticals USA, Inc. | ABILIFY ASIMTUFII, ABRYSVO, AJOVY, AUSTEDO XR, CAPLYTA, COMIRNATY, INGREZZA, Kerendia, PREVNAR 20, PURIFIED CORTROPHIN GEL, REXULTI, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error